Trials / Terminated
TerminatedNCT00758342
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost 0.004% + Brinzolamide 1.0% | Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily) |
| DRUG | Travoprost 0.004% + Tears Natural | Travoprost 0.004% (once daily) + Tears Naturale (twice daily) |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2008-09-25
- Last updated
- 2023-12-05
- Results posted
- 2010-02-05
Source: ClinicalTrials.gov record NCT00758342. Inclusion in this directory is not an endorsement.